特寶生物(688278.SH):選舉公司董事/總經理孫黎為董事長
格隆匯 8 月 31日丨特寶生物(688278.SH)公佈,公司董事會於近日收到董事長蘭春的書面辭職報告:蘭春因工作原因,申請辭去董事長及董事會戰略委員會主任委員、薪酬與考核委員會委員、提名委員會委員等職務,其辭任後將繼續擔任公司董事及戰略委員會委員,仍為公司實際控制人之一。根據《公司法》和《公司章程》的相關規定,上述辭職報告自送達公司董事會之日起生效。
為保證公司董事會的正常運作,依照《公司法》和《公司章程》等有關法律法規和規範性文件的規定,公司於2020年8月31日召開第七屆董事會第十九次會議審議通過《關於選舉公司董事長的議案》,同意選舉公司董事/總經理孫黎為第七屆董事會董事長,任期自董事會審議通過之日起至本屆董事會屆滿之日止。
孫黎,1966年6月出生,中國國籍,擁有新西蘭永久居留權,復旦大學生物學學士,中國科學院微生物研究所碩士,高級工程師,國務院特殊津貼專家。1991年6月至1992年11月就職於湖南醫科大學遺傳國家實驗室,任研究實習員;1992年12月至1995年7月就職於湖南醫科大學湘雅醫院中心實驗室,任助理研究員;公司設立起至2013年4月任總工程師、副總經理,2013年5月至今任公司總經理;現兼任中國生物工程學會醫學生物技術專業委員會副主任委員、中國藥學會生物藥品與質量研究專業委員會委員、第11屆國家藥典委員會委員等,為國家科技部“創新人才推進計劃重點領域創新團隊”負責人,入選福建省“雙百計劃”人才、福建省傑出科技人才,獲中國藥學發展獎、湖南省科學技術進步獎一等獎等多項獎勵。現任公司董事長兼總經理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.